Table 1.
Patients information
| Patient ID | Gender | Age (years) | Primary diagnosis | Failure of disease | Treatment lines | Immunotherapy | Combined chemotherapy | Delay (months) |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 77 | Mandible carcinoma | Recurrence | First line | Toripalimab | Nab-paclitaxel → GEM | 3.27 |
| 2 | M | 73 | Sino-nasal malignant tumors | Metastasis | First line | Pembrolizumab | Nab-paclitaxel | 3.23 |
| 3 | F | 63 | Oral cavity cancer | Metastasis | First line | Pembrolizumab | Nab-paclitaxel | 3.50 |
| 4 | M | 51 | Hypopharyngeal carcinoma | Recurrence | First line | Toripalimab | Nab-paclitaxel | 3.23 |
| 5 | M | 56 | Nasopharyngeal carcinoma | Recurrence | Second line | Toripalimab | S1 | 8.17 |
| 6 | F | 44 | Nasopharyngeal carcinoma | Metastasis | First line | Camrelizumab | GEM | 3.27 |
| 7 | M | 26 | Parotid carcinoma | Metastasis | First line | Camrelizumab | Nab-paclitaxel | 3.23 |
| 8 | M | 53 | Oral cavity cancer | Recurrence | First line | Camrelizumab | GP → nab-paclitaxel | 2.97 |
| 9 | M | 67 | Oral cavity cancer | Recurrence | First line | Toripalimab | GEM | 1.73 |
| 10 | F | 55 | Oral cavity cancer | Recurrence | First line | Pembrolizumab | Nab-paclitaxel | 4.57 |
| 11 | M | 50 | Nasopharyngeal carcinoma | Metastasis | First line | Camrelizumab | Nab-paclitaxel → GEM | 5.57 |
| 12 | M | 65 | Nasopharyngeal carcinoma | Metastasis | First line | Camrelizumab | GEM | 4.13 |
| 13 | M | 46 | Nasopharyngeal carcinoma | Recurrence | First line | Camrelizumab | GP | 3.50 |
| 14 | M | 30 | Oral cavity cancer | Recurrence | First line | Camrelizumab | GP | 4.13 |
| 15 | M | 58 | Oral cavity cancer | Metastasis | First line | Camrelizumab | Nab-paclitaxel | 3.13 |
| 16 | M | 69 | Oral cavity cancer | Recurrence | First line | Pembrolizumab | Nab-paclitaxel | 4.57 |
| 17 | M | 68 | Oral cavity cancer | Recurrence | First line | Camrelizumab | Nab-paclitaxel | 4.00 |
| 18 | M | 67 | Hypopharyngeal carcinoma | Metastasis | Fourth line | Toripalimab | Vinorelbine | 4.27 |
| 19 | M | 73 | Nasopharyngeal carcinoma | Recurrence | First line | Camrelizumab | GEM | 5.37 |
| 20 | M | 52 | Oral cavity cancer | Recurrence | First line | Camrelizumab | GP → nab-paclitaxel | 2.97 |
| 21 | F | 69 | Oral cavity cancer | Metastasis | First line | Toripalimab | GEM | 4.63 |
| 22 | F | 70 | Oral cavity cancer | Metastasis | First line | Camrelizumab | GEM → nab-paclitaxel | 4.37 |
| 23 | M | 58 | Oral cavity cancer | Recurrence | First line | Camrelizumab | Nab-paclitaxel | 3.13 |
| 24 | M | 49 | Nasopharyngeal carcinoma | Recurrence | Fourth line | Toripalimab | Nab-paclitaxel | 6.13 |
M, male; F, female; GEM, gemcitabine; GP, gemcitabine plus cisplatin; S1, gimeracil and oteracil potassium capsules